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Background: B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is characterized by recurrent genetic
alterations including chromosomal translocations. The transcription factor PAX5, which is pivotal for B-cell
commitment and maintenance, is affected by rearrangements, which lead to the expression of in-frame fusion
genes in about 2.5% of the cases.
Results: Using conventional cytogenetics, fluorescence in situ hybridization (FISH), and molecular methods, an
additional case with a der(9)t(7;9)(q11.23;p13) resulting in the expression of a PAX5-ELN fusion gene was identified.
Furthermore, a general review of leukemia harboring a t(7;9)(q11.2;p13) or der(9)t(7;9)(q11.2;p13), which occurs more
often in children than in adults and shows a remarkably high male preponderance, is given. These cytogenetically
highly similar translocations lead to the expression of one of three different in frame PAX5-fusions, namely with
AUTS2 (7q11.22), ELN (7q11.23), or POM121 (7q11.23), which constitute the only currently known cluster of PAX5
partner genes.
Conclusion: Our report underlines the recurrent involvement of PAX5 in different fusion genes resulting either from
t(7;9)(q11.2;p13) or der(9)t(7;9)(q11.2;p13), which cannot be distinguished cytogenetically and whose discrimination
requires molecular analysis.
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PAX5 rearrangements, resulting in the expression of in-
frame fusion genes, account for about 2.5% of pediatric B-
cell precursor acute lymphoblastic leukemia (BCP-ALL)
[1]. While several groups, including our own, have re-
ported the incidence and diversity of PAX5 fusion genes
[1-7], their occurrence in leukemia harboring a t(7;9)
(q11.2;p13) or der(9)t(7;9)(q11.2;p13) has not yet been in-
vestigated in detail. Herein, we describe an additional case
with a PAX5-ELN fusion and summarize the demographic
and genetic data of all cases with t(7;9)(q11.2;p13)/der(9)t
(7;9)(q11.2;p13) leukemia reported to date.
Case presentation
We have identified an additional case of pediatric BCP-
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stated.in the expression of an in-frame PAX5-ELN fusion gene
(Table 1). Cytogenetic analysis of the bone marrow of a
19.4-year-old adolescent revealed - together with many sec-
ondary aberrations - a der(9)t(7;9)(q11.2;p13) (Figure 1A)
and subsequent FISH analysis using PAX5-flanking BAC
clones showed a deletion of the 3′-end-specific probe, which
is suggestive of a PAX5 gene rearrangement (Figure 1B).
Further FISH analysis, using PAX5- and ELN-specific
clones, identified ELN as the fusion partner (Figure 1C),
which was verified on the molecular level by RT-PCR
(Figure 1D). Sequencing of the amplification product
showed that exon 7 of PAX5 was fused to exon 5 of
ELN (Figure 1E). In all PAX5-ELN cases, except for
one in which PAX5 exon 5 was fused to ELN se-
quences, the breakpoints in PAX5 occurred in intron 7
[2,4,8]. Also, the breakpoints in ELN are heterogeneous
and PAX5 is fused to either exon 2 or exon 5 of ELN
(Table 1) [2,4,8]. Consequently, the consensus PAX5-
ELN fusion protein consists of the DNA-binding paired
domain, the octapeptide, and the nuclear localizationtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Demographic and genetic data of t(7;9)(q11.2;p13) and der(9)t(7;9)(q11.2;p13) positive B-ALL cases
Case Age Sex Phenotype Karyotype PAX5 fusion gene Reference
1 37 M B-III 46,XY,t(7;9)(q11;p13)[17] PAX5 ex7/ELN ex2 [2]
2 16 M B-II 46,XY,t(7;9)(q11;p13),del(9)(p21)[14]/ PAX5 ex7/ELN ex2 [2]
46,XY[1]
3 4 M B-I 46,XY,t(7;9)(q11;p13)[2]/ PAX5 ex7/ELN ex2 [4]
46,XY[18]
4 1.4 M B-ALL NA (9906_037) PAX5 ex5/ELN* [8]
5 19.4 M B-III 46,XY,?add(4)(q2?),?add(5)(p14),del(8)(p21),der(9)t(7;9)(q11.2;p13), PAX5 ex7/ELN ex5 This work
del(16)(p13),inc[cp16]/46,idem,?dup(1)(q21)[3]/46,XY[4]
6 3.1 M B-III 45,XY,-7,der(9)t(7;9)(q11;p13)[15]/ PAX5 ex6/AUTS2 ex4 [5]
46,XY[1]
7 2.8 F B-III 45,XX,-7,der(9)t(7;9)(q11;p13),dup(16)(p11p13)[14]/ PAX5 ex6/AUTS2 ex6 [9]
46,XX[2]
8 0.6 M B-II/III 46,XY,t(7;9)(q11;p13)[8] PAX5 ex6/AUTS2 ex5 [10]
9 2.1 M B-III 46,XY,del(7)(q22q33)?,del(9)(q22?),del(12)(p11)[8] PAX5 ex5/POM121 ex4 [1]
10 1 M B-III 46,XY,t(7;9)(q11;p13)[21]/ PAX5 ex5/POM121 ex4 [4]
46,XY[3]
11 1.7 F B-ALL 45,XX,-7,der(9)t(7;9)(q11;p13)[17] NA [12]
46,XX[2]
12 1.3 M B-ALL 45,XY,inv(1)(p35q32),-7,der(9)t(7;9)(q11;p13)[31] NA [13]
46,XY[17]
All cases, except cases 4 and 9, are listed in the Mitelman database from which also the respective karyotypes have been retrieved [11].
*PAX5 exon 5 is fused to an unknown ELN exon.
NA, data not available.
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ELN protein without the signal peptide (Figure 2).
Results and discussion
So far, sixteen in-frame PAX5-fusions have been de-
scribed and the fusion partners comprise a heteroge-
neous group of genes encoding proteins, which play
distinct roles in signaling, transcription, chromatin re-
modeling, and cell structuring [1-7,9,10]. Three of the
sixteen currently known PAX5 fusion partners, namely,
AUTS2, ELN, and POM121, are located at the pericen-
tromeric region of 7q and encompass roughly 3.3 Mb of
genomic DNA, forming the only currently known cluster
of PAX5 partner genes. Therefore, t(7;9)(q11.2;p13)
translocations may give rise to three different recurrent
fusion genes, i.e. PAX5-AUTS2, PAX5-POM121, and
PAX5-ELN (Figure 2), which are not distinguishable at
the cytogenetic level. In addition, karyotyping of five of
the cases showed an unbalanced der(9)t(7;9)(q11.2;
p13) with loss of the reciprocal derivative chromosome
(Table 1; cases 5–7 and 11–12). One of the cases was
identified by SNP array (case 4), only detecting unbal-
anced chromosome alterations; furthermore, most
cases showed a deletion of the PAX5 3′-end by FISH,
further supporting the notion that the PAX5-partnerfusions, and not the reciprocal ones contribute to
leukemogenesis.
t(7;9)(q11.2;p13)/der(9)t(7;9)(q11.2;p13) positive leukemia
is a rare disease and only 9 cases have been collected in
the Mitelman database of the cancer genome anatomy
project ([11] accessed November 2013) (Table 1). Three of
these cases were PAX5-ELN positive [2,4] and in addition,
a case with a PAX5-ELN fusion without cytogenetic data
has been reported [8]. Together, including the case de-
scribed herein, five patients harboring this fusion gene
have now been identified.
Other cases involving the cluster of PAX5 fusion part-
ners include: Three patients with a PAX5-AUTS2 [5,9,10],
two with a PAX5-POM121 fusion gene [1,4], and in two
cases involvement of PAX5 has not been investigated
[12,13] (Table 1). Of note, in the PAX5-POM121 case we
have previously published [1], cytogenetic analysis failed
to identify a t(7;9)(q11.2;p13), but the chromosome quality
was rather poor. Whole chromosome painting with
probes specific for chromosomes 7 and 9 showed the
presence of a der(7;9), on which the 3′-end of PAX5 was
located, whereas the 5′-end of PAX5, generating the
PAX5-POM121 fusion, was translocated to a derivative
chromosome, which only partially consisted of chromo-
some 7 material (data not shown). Together, with the
Figure 2 Schematic representation of the structure of PAX5 and the putative consensus chimeric proteins. PD, paired domain; 8,
octapeptide; HD, partial homeodomain; TA, transactivation domain; I, inhibitory domain; P, proline-rich regions; H, histidine-rich regions; KA,
alanine-rich cross-linking domains; KP, proline-rich cross-linking domains; HY, hydrophobic domains; 6, VGVAPG hexapeptide domain; C, C-terminal
domain; i, insertion; N, POM121 5′-untranslated region; FG, FG-repeats; arrows and filled lollipops indicate nuclear localization signals and fusion
breakpoints, respectively.
Figure 1 Cytogenetic and molecular genetic analysis of a PAX5-ELN positive case. (A) Karyogram; red arrow indicates the derivative
chromosome der(9)t(7;9)(q11.23;p13) (refined karyotype using molecular methods). (B) FISH using PAX5-specific BAC clones showing a 3′-end
deletion: 5′-end-specific clone (red signals); 3′-end-specific clone (green signals); black and red arrows indicate the normal and derivative
chromosome, respectively. (C) FISH using PAX5- and ELN-specific BAC clones showing a co-localization: PAX5 5′-end-specific clone (red signals);
ELN 3′-end-specific clone (green signals); arrows indicate the normal chromosomes 9 and 12 (white) and the derivative chromosome (black).
(D) RT-PCR using primers located in PAX5 exon 2–3 and ELN exon 6 resulting in amplification of PAX5-ELN fusion transcripts. M, molecular weight
marker DNA-mix ladder (Peqlab); lane 1, patient No. 5; lane 2, normal control. (E) Sequence chromatogram of the PAX5-ELN fusion junction
showing the fusion between exon 7 of PAX5 and exon 5 of ELN.
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12 sequences in the fusion, a more complex rearrange-
ment with involvement of at least chromosomes 7, 9, and
12 generated the in-frame PAX5-POM121 fusion [1].
Furthermore, out of the 12 cases with t(7;9)(q11.2;p13)/
der(9)t(7;9)(q11.2;p13) rearrangements only one was an
adult and two were young adolescents, whereas all other
patients were ≤ 4 years of age (Table 1), suggesting that
this subtype of leukemia occurs more frequently in
pediatric than in adult cases. Remarkably, 83% (10/12)
of the t(7;9)(q11.2;p13)/der(9)t(7;9)(q11.2;p13) patients
were male, and thus, the male/female ratio was 5. Al-
though the number of so far reported cases is rather
low, in acute leukemia such an extreme gender bias is
exceedingly rare [14]. This finding is intriguing, but cur-
rently there is no plausible explanation why a specific
subtype of leukemia is associated with one or the other
gender.
Regarding the prognostic relevance of PAX5 fusion
genes in general, due to their rareness no final conclu-
sions may be drawn. However, we have recently shown
that PAX5-AUTS2 leukemia may have a rather unfavor-
able outcome [10]. Out of the five PAX5-ELN cases, one
patient (case 4) showed high-risk features and displayed
a JAK1 mutation and a BCR-ABL1-like expression signa-
ture [8]. Furthermore, cases 1 and 2 both relapsed post
allograft and died 16 months after initial diagnosis ([15]
accessed November 2013). The PAX5-ELN positive pa-
tient presented herein is currently, eight months after
initial diagnosis, in complete remission. Together, there
is at least some evidence that t(7;9)(q11.2;p13)/der(9)t
(7;9)(q11.2;p13) leukemia may have a rather poor progno-
sis. However, whether this is attributable to the specific
PAX5-fusions or to coinciding mutations in, for example,
tyrosine kinases, remains to be determined, and a larger
cohort of patients needs to be analyzed, which, due to the
low incidence of this leukemia subtype, will require an
international collaborative effort.
Conclusion
In this report an additional case of PAX5-ELN positive
leukemia is described, and, furthermore, an overview of
the published cases of t(7;9)(q11.2;p13)/der(9)t(7;9)(q11.2;
p13) leukemia is given, emphasizing the importance of
molecular analysis to discriminate between cytogenetically
identical translocations resulting in distinct fusion genes.
Material and methods
Cytogenetic and fluorescence in situ hybridization (FISH)
analysis
Cytogenetic analysis was performed according to standard
techniques. FISH analysis using PAX5- and ELN-specific
probes was conducted as previously described [1]. ThePAX5 rearrangement was first detected using PAX5-
flanking BAC clones RP11-220I1 and RP11-12P15 (ob-
tained from Pieter de Jong, BACPAC Resources, Children’s
Hospital and Research Center Oakland, CA, USA).
Verification of the PAX5-ELN fusion was performed
using the PAX5 5′-end-flanking BAC clone RP11-
220I1 in combination with the ELN 3′-end-specific
clone RP11-349P21 (Welcome Trust Sanger Institute;
http://www.sanger.ac.uk).RNA isolation and reverse transcription-polymerase chain
reaction (RT-PCR)
RNA isolation and RT-PCR for the detection of PAX5-ELN
transcripts were performed according to standard proce-
dures using primers PAX5ex2-3-F1 (5′-TCTTGGCAGG
TATTAT GAGACAGGAAG-3′) and ELNex6-R2 (5′-A
GCAGCGTCAGCCACTCCAC-3′) located in exons 2–
3 and 6 of PAX5 and ELN, respectively. Amplification
products were directly sequenced (Microsynth AG, Austria)
and sequence analysis was conducted using the CLC Main
Workbench 6.0 (CLC bio, Denmark).Reference sequences and exon nomenclature
The chromosome band positions of the genes and the
exon nomenclature used correspond to that of the En-
semble database and the reference sequences for AUTS2
(ENST00000342771), ELN (ENST00000252034), POM121
(ENST00000257622), and PAX5 (ENST00000358127)
(Ensembl release 73 - September 2013). A summary of all
mRNA fusion sequences as well as the entire transcript
and protein sequences of the putative consensus chimeras
PAX5-AUTS2, PAX5-ELN, and PAX5-POM121 are pro-
vided as Additional file 1.Consent
Within the AIEOP-BFM ALL 2009 study (ClinicalTrials.
gov Identifier: NCT01117441), written informed consent -
which includes the compliance that surplus material not
required for diagnostic purposes may be used for research
purposes - is obtained from the patients, their parents or
their legal guardians. This study has exclusively been per-
formed on material obtained for diagnostic purposes and
neither any additional medical intervention nor patient re-
cruitment was necessary.Additional file
Additional file 1: PAX5 fusion genes in t(7;9)(q11;p13) leukemia: A
case report and review of the literature.Competing interests
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